DIAGNOSTIC AND THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING PTEN AND BREAST CANCER

摘要

Patients with ErB2-overxprsessing cancers can be given an ErB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErB2 targeting agent in an ErB2-overxpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.